{"denoms":[{"counts":[{"groupId":"BG000","value":"5"}],"units":"Participants"}],"groups":[{"id":"BG000","title":"Subcutaneous Bortezomib"}],"measures":[{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"5.1","value":"62"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Gender","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}]}],"paramType":"NUMBER","title":"The patients were required to have received a prior IV bortezomib containing combination regimen tha","unitOfMeasure":"participants"}]}